Changes necessary to ensure and maintain the continued suitability, adequacy, and effectiveness of the quality management system and medical device safety and performance were not adequately identified and implemented.
Inspection Record
Nanovis LLC — FDA 483 Findings
Inspectors Suyang Qin · Shawn ChoiThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Procedures for validation of processes did not adequately include statistical techniques with rationale for sample sizes and use of specific methods, procedures, and acceptance criteria.
Purchasing information does not adequately describe or reference the product to be purchased, including requirements for product acceptance, procedures, processes, and equipment.
Requirements for the work environment, and the procedures to monitor and control the work environment, were not adequately documented where conditions for the work environment can have an adverse effect on product quality.
Changes to quality management system processes were not adequately controlled in accordance with requirements and evaluated for their impact on the quality management system and the medical devices produced.
Production controls do not include implementation of monitoring and measurement of process parameters and product characteristics.
A record as of the US FDA document published on 2026-11-12. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.